These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 22329188)

  • 1. Evolution of treatment options for patients with CRPC and bone metastases: bone-targeted agents that go beyond palliation of symptoms to improve overall survival.
    Rove KO; Crawford ED
    Oncology (Williston Park); 2011 Dec; 25(14):1362-70, 1375-81, 1387. PubMed ID: 22329188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress in the treatment of bone metastases in cancer patients.
    Mackiewicz-Wysocka M; Pankowska M; Wysocki PJ
    Expert Opin Investig Drugs; 2012 Jun; 21(6):785-95. PubMed ID: 22500564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies.
    Saad F; Colombel M
    Expert Rev Anticancer Ther; 2010 Dec; 10(12):1991-2002. PubMed ID: 21110764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The systemic treatment of bone metastases.
    Houston SJ; Rubens RD
    Clin Orthop Relat Res; 1995 Mar; (312):95-104. PubMed ID: 7543393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone targeted therapies in metastatic castration-resistant prostate cancer.
    Rajpar S; Fizazi K
    Cancer J; 2013; 19(1):66-70. PubMed ID: 23337759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment options in androgen-independent prostate cancer.
    Lara PN; Meyers FJ
    Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone-targeted therapies to reduce skeletal morbidity in prostate cancer.
    Dorff TB; Agarwal N
    Asian J Androl; 2018; 20(3):215-220. PubMed ID: 29553053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural history and treatment of bone complications in prostate cancer.
    Saad F; Clarke N; Colombel M
    Eur Urol; 2006 Mar; 49(3):429-40. PubMed ID: 16431012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid.
    Saad F; Segal S; Eastham J
    Eur Urol; 2014 Jan; 65(1):146-53. PubMed ID: 22633317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of bone metastases in urologic malignancies.
    Froehner M; Hölscher T; Hakenberg OW; Wirth MP
    Urol Int; 2014; 93(3):249-56. PubMed ID: 25115989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrating bone targeting radiopharmaceuticals into the management of patients with castrate-resistant prostate cancer with symptomatic bone metastases.
    Blacksburg SR; Witten MR; Haas JA
    Curr Treat Options Oncol; 2015 Mar; 16(3):325. PubMed ID: 25777571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic options for hormone-refractory prostate cancer in 2007.
    Hadaschik BA; Gleave ME
    Urol Oncol; 2007; 25(5):413-9. PubMed ID: 17826663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of bone-targeted agents on cancer progression and mortality.
    Coleman R; Gnant M; Morgan G; Clezardin P
    J Natl Cancer Inst; 2012 Jul; 104(14):1059-67. PubMed ID: 22752060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
    Higano CS
    Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-line treatment of metastatic prostate cancer. Prednisone and radiotherapy for symptom relief.
    Prescrire Int; 2013 Mar; 22(136):74-8. PubMed ID: 23593699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy.
    Saad F; Sternberg CN
    Nat Clin Pract Urol; 2007 Feb; 4 Suppl 1():S3-13. PubMed ID: 17264863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
    Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
    J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of bone metastases in patients with castration-resistant prostate cancer.
    Cathomas R; Bajory Z; Bouzid M; El Ghoneimy A; Gillessen S; Goncalves F; Kacso G; Kramer G; Milecki P; Pacik D; Tantawy W; Lesniewski-Kmak K
    Urol Int; 2014; 92(4):377-86. PubMed ID: 24802278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone-directed treatments for prostate cancer.
    Saad F
    Hematol Oncol Clin North Am; 2006 Aug; 20(4):947-63. PubMed ID: 16861125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radionuclide therapy for osseous metastases in prostate cancer.
    Abi-Ghanem AS; McGrath MA; Jacene HA
    Semin Nucl Med; 2015 Jan; 45(1):66-80. PubMed ID: 25475380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.